{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:40:19Z","timestamp":1793090419072,"version":"4.5.0"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.16199","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:02:49Z","timestamp":1654700569000},"page":"e2216199","source":"Crossref","is-referenced-by-count":93,"title":["Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma"],"prefix":"10.1001","volume":"5","author":[{"given":"Avital","family":"Klein-Brill","sequence":"first","affiliation":[{"name":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shlomit","family":"Amar-Farkash","sequence":"additional","affiliation":[{"name":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Collisson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dvir","family":"Aran","sequence":"additional","affiliation":[{"name":"Anthem Innovation Israel, Ltd, Tel Aviv, Israel"},{"name":"Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel"},{"name":"The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel"},{"name":"Lorry I. Lokey Interdisciplinary Center for Life Sciences and Engineering, Technion-Israel Institute of Technology, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,6,8]]},"reference":[{"issue":"19","key":"zoi220472r2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi220472r3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju413","article-title":"Nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.","volume":"107","author":"Goldstein","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"zoi220472r4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.conctc.2018.08.001","article-title":"Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review.","volume":"11","author":"Fogel","year":"2018","journal-title":"Contemp Clin Trials Commun"},{"issue":"5","key":"zoi220472r5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ijc.v144.5","article-title":"Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma.","volume":"144","author":"Hegewisch-Becker","year":"2019","journal-title":"Int J Cancer"},{"issue":"3","key":"zoi220472r6","doi-asserted-by":"publisher","first-page":"566","DOI":"10.21037\/jgo","article-title":"Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer.","volume":"8","author":"Muranaka","year":"2017","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"zoi220472r7","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/cam4.v9.1","article-title":"Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: a population-based propensity score-weighted analysis.","volume":"9","author":"Chan","year":"2020","journal-title":"Cancer Med"},{"key":"zoi220472r8","doi-asserted-by":"publisher","first-page":"x69","DOI":"10.1093\/annonc\/mdx660.040","article-title":"Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan.","volume":"28","author":"Maeda","year":"2017","journal-title":"Ann Oncol"},{"key":"zoi220472r9","doi-asserted-by":"publisher","first-page":"ii11","DOI":"10.1093\/annonc\/mdu164.18","article-title":"An indirect treatment comparison and cost-effectiveness analysis comparing FOLFIRINOX with nab-paclitaxel plus gemcitabine for first-line treatment for patients with metastatic pancreatic cancer.","volume":"25","author":"Hollmann","year":"2014","journal-title":"Ann Oncol"},{"key":"zoi220472r10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejca.2021.03.040","article-title":"Gemcitabine\/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis.","volume":"151","author":"Riedl","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"zoi220472r11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1186\/s12885-021-08277-7","article-title":"Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.","volume":"21","author":"Chun","year":"2021","journal-title":"BMC Cancer"},{"issue":"2","key":"zoi220472r12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.37120","article-title":"Association of performance status with survival in patients with advanced non\u2013small cell lung cancer treated with pembrolizumab monotherapy.","volume":"4","author":"Sehgal","year":"2021","journal-title":"JAMA Netw Open"},{"key":"zoi220472r13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/POR","article-title":"A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data.","volume":"8","author":"Kern","year":"2017","journal-title":"Pragmat Obs Res"},{"issue":"6","key":"zoi220472r15","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6601231","article-title":"Performance status score: do patients and their oncologists agree?","volume":"89","author":"Blagden","year":"2003","journal-title":"Br J Cancer"},{"issue":"6","key":"zoi220472r16","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/sj.bjc.6601242","article-title":"Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non\u2013small-cell lung cancer.","volume":"89","author":"Forrest","year":"2003","journal-title":"Br J Cancer"},{"issue":"23","key":"zoi220472r17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.21105\/joss","article-title":"Comorbidity: an R package for computing comorbidity scores.","volume":"3","author":"Gasparini","year":"2018","journal-title":"J Open Source Softw"},{"issue":"24","key":"zoi220472r19","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Analyzing survival curves at a fixed point in time.","volume":"26","author":"Klein","year":"2007","journal-title":"Stat Med"},{"issue":"8","key":"zoi220472r20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: nonparametric preprocessing for parametric causal inference.","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"zoi220472r21","article-title":"An evaluation toolkit to guide model selection and cohort definition in causal inference.","author":"Shimoni","journal-title":"arXiv"},{"issue":"36","key":"zoi220472r22","doi-asserted-by":"publisher","first-page":"5918","DOI":"10.1200\/JCO.2008.18.6288","article-title":"Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704.","volume":"26","author":"Berger","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi220472r23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040484","article-title":"Comparative effectiveness of gemcitabine plus nab-paclitaxel and FOLFIRINOX in the first-line setting of metastatic pancreatic cancer: a systematic review and meta-analysis.","volume":"11","author":"Pusceddu","year":"2019","journal-title":"Cancers (Basel)"},{"key":"zoi220472r1","unstructured":"American Cancer Society. Key Statistics for Pancreatic Cancer. Revised January 21, 2022. Accessed April 12, 2022. https:\/\/www.cancer.org\/cancer\/pancreatic-cancer\/about\/key-statistics.html"},{"key":"zoi220472r14","unstructured":"US Department of Health and Human Services. The HIPPA privacy rule. Reviewed March 31, 2022. Accessed May 5, 2022. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/index.html"},{"key":"zoi220472r18","unstructured":"US Department of Health and Human Services. Guidance regarding methods for de-identification of protected health information in accordance with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. Reviewed November 6, 2015. Accessed May 5, 2022. https:\/\/www.hhs.gov\/hipaa\/for-professionals\/privacy\/special-topics\/de-identification\/index.html#safeharborguidance"},{"key":"zoi220472r24","unstructured":"UpToDate. FOLFIRINOX for metastatic pancreatic cancer. Updated March 25, 2022. Accessed April 12, 2022. https:\/\/www.uptodate.com\/contents\/image?imageKey=ONC%2F79571"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2793152\/kleinbrill_2022_oi_220472_1654027880.97462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T15:02:54Z","timestamp":1654700574000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2793152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.16199","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,8]]}}}